SEARCH:   Advanced

This Article Abstract Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Rights and Permissions Citing Articles Citing Articles via HighWire Citing Articles via CrossRef Citing Articles via Google Scholar Google Scholar Articles by Sternberg, D. W. Articles by Gilliland, D. G. Search for Related Content PubMed PubMed Citation Articles by Sternberg, D. W. Articles by Gilliland, D. G. Related Collections Neoplasia Signal Transduction Social Bookmarking                   What's this?  Previous Article  |  Table of Contents  |  Next Article  Blood, 1 December 2001, Vol. 98, No. 12, pp. 3390-3397 NEOPLASIA The TEL/PDGFR fusion in chronic myelomonocytic leukemia signals through STAT5-dependent and STAT5-independent pathways David W. Sternberg, Michael H. Tomasson, Martin Carroll, David P. Curley, George Barker, Michael Caprio, Alyson Wilbanks, Andrius Kazlauskas, and D. Gary Gilliland From the Howard Hughes Medical Institute, Harvard Medical School, Schepens Eye Research Institute, and Brigham and Women's Hospital, Boston, MA.     Abstract Top Abstract Introduction Materials and methods Results Discussion References The TEL/PDGFR gene, which encodes a fusion protein containing the ETS-family member TEL fused to the protein-tyrosine kinase domain of the platelet-derived growth factor receptor- (PDGFR), confers interleukin 3 (IL-3)-independent growth on Ba/F3 hematopoietic cells. TEL/PDGFR mutants have been generated that contain tyrosine-to-phenylalanine (TyrPhe) substitutions at phosphorylation sites present in the native PDGFR to assess the role of these sites in cell transformation by TEL/PDGFR. Similar to previous findings in a murine bone marrow transplantation model, full transformation of Ba/F3 cells to IL-3-independent survival and proliferation required the TEL/PDGFR juxtamembrane and carboxy terminal phosphorylation sites. In contrast to previous reports concerning comparable mutants in the native PDGFR, each of the TEL/PDGFR mutants is fully active as a protein-tyrosine kinase. Expression of the TEL/PDGFR fusion protein causes hyperphosphorylation and activation of signal transducer and activator of transcription (STAT5), and this activation of STAT5 requires the juxtamembrane Tyr579 and Tyr581 in the TEL/PDGFR fusion. Hyperphosphosphorylation of phospholipase C (PLC) and the p85 subunit of phosphatidylinositol 3-kinase (PI3K) requires the carboxy terminal tyrosine residues of TEL/PDGFR. Thus, full transformation of Ba/F3 cells by TEL/PDGFR requires engagement of PI3K and PLC and activation of STAT5. Taken together with the growth properties of cells transformed by the TEL/PDGFR variants, these findings indicate that a minimal combination of these signaling intermediates contributes to hematopoietic transformation by the wild-type TEL/PDGFR fusion. (Blood. 2001;98:3390-3397) © 2001 by The American Society of Hematology.     Introduction Top Abstract Introduction Materials and methods Results Discussion References Chronic myelomonocytic leukemia (CMML) is characterized by clonal proliferation of myeloid cells and frequent progression to acute leukemia. A recurring cytogenetic abnormality in CMML is the t(5;12)(q33;p13) chromosomal translocation. The resulting gene rearrangement fuses the 5' region of TEL to the gene encoding the platelet-derived growth factor receptor- (PDGFR).1 TEL is a member of the ETS family of transcription factors, and it consists of an amino terminal Pointed domain (PNT) and a carboxy terminal DNA-binding domain that shares sequence homology with the winged helix-turn-helix motif. In the TEL/PDGFR fusion protein, the amino terminal region of TEL (which contains the PNT domain) is fused to the membrane-spanning segment and the entire cytoplasmic protein-tyrosine kinase domain of PDGFR. The PNT domain present in the TEL segment mediates homotypic oligomerization of the fusion protein.2,3 Fusion of TEL sequences to PDGFR results in constitutive oligomerization and activation of protein-tyrosine kinase activity2; numerous examples of receptor tyrosine kinase activation through homotypic oligomerization have been described (reviewed by Lemmon and Schlessinger4). The Ba/F3 murine hematopoietic cell line, which requires interleukin-3 (IL-3) for survival,5 can be transformed to IL-3 independence by the TEL/PDGFR fusion.2 TEL/PDGFR is constitutively phosphorylated on tyrosine residues, and a point mutation corresponding to a kinase-inactivating mutation in the native PDGFR abrogates TEL/PDGFR kinase activation and transformation of Ba/F3 cells. Moreover, the PDGFR tyrosine kinase inhibitor CGP 571486 inhibits TEL/PDGFR kinase activity in vitro, inhibits autophosphorylation in vivo, and abrogates proliferation of Ba/F3 cells transformed by TEL/PDGFR.7 Thus, hematopoietic transformation by TEL/PDGFR requires protein-tyrosine kinase activity. Similar structure-function relationships have been described for the HIP1/PDGFR fusion8,9 associated with the t(5;7)(q33;q11.2) translocation, and the H4/PDGFR fusion that is expressed as a consequence of the t(5;10)(q33;q22) translocation.10 Each of these PDGFR fusions is associated with a phenotype of CMML in humans, but contains a different amino terminal fusion partner and oligomerization motif that serves to activate the PDGFR kinase activity. These observations suggest that the critical event in the pathogenesis of CMML is the activation of the PDGFR kinase activity and the subsequent activation of downstream signaling pathways in hematopoietic cells. Multiple signaling pathways are engaged following ligand activation of the native PDGFR.11-13 The native PDGFR autophosphorylates on multiple tyrosine residues that provide docking sites for signaling proteins through their respective SH2 phosphotyrosine-binding domains. Interaction with such intermediates as Src family members, phosphatidylinositol 3-kinase (PI3K), Ras GTPase-activating protein (RasGAP), phospholipase C- (PLC), the Grb2 small adaptor molecule, and the SHP-2 tyrosine phosphatase have been implicated in signaling by the activated PDGFR. Moreover, PDGF has been shown previously to induce phosphorylation of multiple STAT proteins and JAK kinases.14 The signal transducers and activators of transcription (STATs) comprise a family of cytoplasmic proteins that are hyperphosphorylated in response to mitogen stimulation; they dimerize, translocate to the nucleus, and serve as transcriptional activators.15 Oncogenic fusion proteins such as P210 and P190BCR/ABL,16 TEL/JAK2 fusion variants,17-19 and TEL/PDGFR20 are each able to cause constitutive STAT signaling. The TEL/PDGFR fusion protein might support hematopoietic cell survival and proliferation through pathways similar to those used by the native PDGFR. We constructed a series of tyrosine-to-phenylalanine (TyrPhe) mutants in TEL/PDGFR at positions corresponding to major autophosphorylation sites in PDGFR. Although each of the TEL/PDGFR variants was able to transform Ba/F3 cells to IL-3-independent growth and survival, there was a marked prolongation in disease latency in a murine bone marrow transplant (BMT) assay with increasing TyrPhe substitution.21 In striking contrast to our findings using the in vitro Ba/F3 culture system, the ability of TEL/PDGFR to cause a myeloproliferative disease in the murine BMT assay was markedly attenuated by substitution at the juxtamembrane phosphorylation sites, and bone marrow transduced with these mutants yielded a lymphoproliferative disease rather than myeloid leukemia. We were puzzled by the disparity in these results, and we further characterized the transformation of hematopoietic cells in vitro to better understand the role of individual signaling pathways in each of these model systems. Here we show that phosphorylation of both the juxtamembrane and carboxy terminal tyrosine residues in TEL/PDGFR is necessary for full transformation in the Ba/F3 assay, and these results are consistent with our previous observations in the murine BMT model.21 Moreover, the juxtamembrane tyrosines Tyr579 and Tyr581 in TEL/PDGFR are necessary for full activation of STAT5, whereas the carboxy terminal tyrosines are necessary for engagement of PLC and PI3K. Taken together, these findings indicate that activation of STAT5 and engagement of PLC and PI3K are necessary for full transformation of IL-3-independent Ba/F3 cells.     Materials and methods Top Abstract Introduction Materials and methods Results Discussion References Cell culture and retroviral infections The murine precursor line Ba/F3 was kindly provided by Alan D'Andrea (Dana-Farber Cancer Institute, Boston, MA). The murine myeloid line 32D was a gift from Dong-Er Zhang (Beth Israel-Deaconess Medical Center, Boston, MA). Ba/F3 and 32D cells transformed with MSCV constructs were maintained in RPMI 1640 medium supplemented with 10% fetal bovine serum, 1.0 ng/mL of recombinant IL-3 (R & D Systems, Minneapolis, MN), and 1.0 mg/mL G418 in a 5% CO2 incubator at 37°C. Cells were passaged when they reached a density of approximately 0.5 to 1 × 106/mL. For growth curve assays, Ba/F3 cells were infected with each of the MSCV retroviral constructs and were grown in the presence of IL-3 for 2 days. G418 selection was performed for an additional 15 days in the presence of IL-3. Cells were washed and resuspended in medium containing G418 without IL-3. These populations were maintained at a density of 1 × 105 to 1 × 106/mL. DNA constructs The TEL/PDGFR variants were constructed using native PDGFR F-series mutants described previously.22 The 2.4-kb TEL/PDGFR complementary DNA (cDNA) was subcloned into the multicloning site of the MSCVneoEB retroviral vector containing a modified murine Maloney leukemia virus long terminal repeat (LTR), and a neomycin-resistance cassette (provided by R. Hawley, Red Cross, Rockville, MD). TEL/PDGFR TyrPhe mutants were generated by subcloning F2, F5, and F7 PDGFR mutants (provided by A. Kazlauskas, Boston, MA) into the TEL/PDGFR background. Protein extracts and immunoprecipitations The Ba/F3 cells were grown to a density of approximately 1 × 106/mL. Cells were collected by centrifugation and washed in 5 to 10 mL phosphate-buffered saline (PBS) at 4°C. Cells were lysed in 1.0 mL lysis buffer: 20 mM Tris-HCl, pH 7.4, 1% Triton X-100, 0.5 mM EDTA, 150 mM NaCl, 1 mM Na3VO4, 25 mM NaF, 10% glycerol, and complete protease inhibitor cocktail (Roche, Indianapolis, IN). Lysates were incubated for 5 minutes at 4°C and were then cleared by centrifugation at 14 000g for 10 minutes at 4°C. For the assessment of STAT5 phosphorylation in the 32D cell line, cells were washed with PBS supplemented with 0.4 mM Na3VO4, and 20 µM phenylarsine oxide was added to the lysis buffer. Freshly prepared lysates were used for all immunoprecipitations. Immunoprecipitations were performed by incubating 500 to 1000 µg total cell lysate on a rocker at 4°C for 1 to 2 hours with either polyclonal rabbit anti-PDGFR tail serum (Pharmingen, San Diego, CA), rabbit anti-PI3K (p85) antiserum (Upstate Biotechnology, Lake Placid, NY), or antibovine PLC-1 mixed monoclonal IgG (Upstate Biotechnology). Rabbit polyclonal antibodies against Grb2, RasGAP, STAT5b (which also recognizes STAT5a), or SHP-2 were from Santa Cruz Biotechnology (Santa Cruz, CA). Immunoprecipitates were collected with protein A-Sepharose (Amersham-Pharmacia Biotech, Piscataway, NJ) for rabbit polyclonal antibodies or protein G-Sepharose (Pharmacia Biotech) for mouse monoclonal antibodies. Immunoprecipitates were washed 3 times in lysis buffer and boiled for 5 minutes in sodium dodecyl sulfate (SDS) sample buffer. Immunoblotting Samples were separated by SDS-polyacrylamide gel electrophoresis (SDS-PAGE) and transferred electrophoretically to either Immobilon-P (Millipore, Cambridge, MA) or to BioBlot-NC (Corning Costar). Samples were blocked with 1% bovine serum albumin (Sigma Fraction V; Sigma Chemicals, St Louis, MO) in wash buffer: 10 mM Tris-HCl, pH 7.4, 0.1% Triton X-100, and 0.9% NaCl. Samples were then incubated for 1 hour with one of the following antibodies: mouse monoclonal 4G10 or horseradish peroxidase (HRP)-conjugated 4G10 antibody against phosphotyrosine (Upstate Biotechnology), polyclonal rabbit anti-PDGFR tail serum (Pharmingen), rabbit anti-PI3K (p85) antiserum (Upstate Biotechnology), anti-PLC-1 monoclonal IgG (Upstate Biotechnology), anti-PTP1D (anti-SHP2) mouse monoclonal IgG (Transduction Laboratories, Lexington, KY), rabbit anti-Grb2 antibody (Santa Cruz Biotechnology), or rabbit anti-STAT5 polyclonal antibody (Santa Cruz Biotechnology). Filters were washed and were incubated with either HRP-conjugated antirabbit IgG or HRP-conjugated antimouse IgG (Amersham). Blots were rinsed and visualized by enhanced chemiluminescence. In vitro protein kinase assay and phosphoamino acid analysis Cell lysates were immunoprecipitated with anti-PDGFR tail antibody as above and washed 3 times with lysis buffer. Immunoprecipitates were washed an additional 2 times with kinase buffer: 20 mM Tris-HCl, pH 7.4, 1 mM Na3VO4, and 10 mM MgCl2. Protein kinase assays were carried out in 30 µL kinase buffer with 10 µCi (0.37 MBq) -[32P]-ATP for 10 minutes at 30°C. Kinase assays were washed twice in lysis buffer and loaded onto 7.5% SDS-PAGE. Extraction of radiolabeled proteins from gel slices, acid hydrolysis, and 2-dimensional electrophoresis of phosphoamino acids were performed as described previously.23 For in vitro kinase assays using exogenous substrate, TEL-PDGFR immune complex kinase assays were performed in the presence of purified bacterial GST-p97 substrate, 20 mM MOPS pH 7.0, 0.2 mM pervanadate, 5 mM MnCl2, 5 µM unlabeled ATP, and 10 µCi (0.37 MBq) -[32P]-ATP. Reactions were carried out for 5 minutes and were stopped with SDS-sample buffer containing 50 mM EDTA. Kinase reactions were fractionated by SDS-PAGE and visualized by autoradiography. Electrophoretic mobility shift assay STAT5 DNA binding was assayed by electrophoretic mobility shift assay (EMSA) as described previously.16,18     Results Top Abstract Introduction Materials and methods Results Discussion References Substitution of the major tyrosine phosphorylation sites present in the native PDGFR impairs cell transformation by the TEL/PDGFR fusion The TEL/PDGFR fusion was stably expressed by retroviral infection in the Ba/F3 hematopoietic cell line, which requires the continuous presence of IL-3 for survival and proliferation. As shown previously,2 transformation by the TEL/PDGFR fusion abrogates the requirement of IL-3 for cell survival and proliferation. In contrast, cells transfected with vector alone are not viable in the absence of IL-3 and undergo apoptotic cell death. The major tyrosine phosphorylation sites are known for the native PDGFR, and these provide critical interaction sites with multiple signaling intermediates that contain SH2 domains. We speculated that similar sites might be necessary for transformation by the TEL/PDGFR fusion. TEL/PDGFR variants were constructed that contained TyrPhe substitutions at each of the major phosphotyrosine interaction sites present in the native PDGFR (Figure 1A). View larger version (25K): [in this window] [in a new window]   Figure 1. Structure, transforming properties, and expression of TEL/PDGFR mutants. (A) Schematic diagram of wild-type (WT) PDGFR and TEL/PDGFR mutants. At left is depicted the wild-type PDGFR protein with the major tyrosine phosphorylation sites denoted. Wild-type and mutant TEL/PDGFR variants are shown that contain TyrPhe substitutions at sites corresponding to phosphorylation sites in the native PDGFR protein. Boxed areas indicate the TEL domain; oval hatched areas denote the split tyrosine kinase domain. Numbering of tyrosine residues corresponds to positions in the wild-type PDGFR protein. (B) Growth properties of Ba/F3 hematopoietic cells stably transformed with wild-type and mutant TEL/PDGFR fusion genes. Ba/F3 cells transformed by pMSCV vector with or without wild-type TEL/PDGFR, F2, F5, F7, or F8 were grown in the absence of IL-3. Cells were maintained at a density of 1 × 105 to 1 × 106/mL. (C) Expression of wild-type and mutant TEL/PDGFR proteins in stably transformed Ba/F3 cells. Cells were lysed and were immunoprecipitated with antibody recognizing the cytoplasmic domain of the PDGFR. Immunoprecipitates were separated by SDS-PAGE and immunoblotted with antibody against the PDGFR cytoplasmic domain. Multiple bands in each lane are the consequence of 2 translational start sites within the TEL gene and of autophosphorylation of TEL/PDGFR. (D) Tyrosine phosphorylation of wild-type and mutant TEL/PDGFR proteins. TEL/PDGFR variants were immunoprecipitated as in panel C and immunoblotted with a monoclonal antibody against protein phosphotyrosine. In our previous report, each of these TEL/PDGFR TyrPhe substitution mutants was able to transform Ba/F3 cells to IL-3 independence,21 but progressive substitution of these tyrosine residues markedly impaired generation of a myeloproliferative disease in a murine BMT model. To further quantify the transformation of Ba/F3 cells by TEL/PDGFR, cells were infected with retrovirus expressing each of the TEL/PDGFR mutants and the neomycin-resistance gene, and cells were then grown for 15 days in the presence of IL-3. IL-3 was then removed from the growth media, and cell proliferation was assayed in the absence of IL-3 (Figure 1B). Substitution of either the juxtamembrane tyrosine residues in the F2 mutant or the carboxy terminal tyrosine residues in the F5 mutant impaired the outgrowth of Ba/F3 cells in the absence of IL-3. Thus, both the juxtamembrane and carboxy terminal phosphorylation sites that are present in the native PDGFR are necessary for full transformation of Ba/F3 cells by TEL/PDGFR. Moreover, substitution of both the juxtamembrane and carboxy tyrosine residues in the F7 and F8 variants substantially attenuated the growth of Ba/F3 cells in the absence of IL-3, and this impairment of TEL/PDGFR transformation was greater than that observed with the individual juxtamembrane or carboxy terminal mutants. No outgrowth of IL-3-independent Ba/F3 cells was observed in cells infected with the empty vector control. Although mutants such as F8 that contain multiple substitutions can ultimately cause IL-3-independent cell outgrowth after long latency,21 the results presented here indicate that both the juxtamembrane and carboxy terminal phosphorylation sites in the TEL/PDGFR fusion are necessary for full Ba/F3 transformation to IL-3 independence. To determine the expression of each of the TEL/PDGFR fusion variants, Ba/F3 cell lysates were immunoblotted with antibody directed against the cytoplasmic tail of the PDGFR protein. As shown in Figure 1C, the wild-type or variant TEL/PDGFR protein was expressed in each of the Ba/F3 cell lines, although the level of wild-type and F5 TEL/PDGFR protein was somewhat reduced in multiple independent Ba/F3 cell lines relative to that in F2, F7, and F8 cell lines. The TEL/PDGFR fusion protein has protein-tyrosine kinase activity The TEL/PDGFR protein contains the entire protein-tyrosine kinase domain of the native PDGFR protein. To confirm that the protein was active as a tyrosine kinase, wild-type TEL/PDGFR protein was immunoprecipitated from Ba/F3 cell lysates and subjected to in vitro autophosphorylation with -[32P]-ATP. The wild-type TEL/PDGFR protein was active in a kinase assay as measured by autophosphorylation (Figure 2A). To determine the amino acid specificity of this kinase, the autophosphorylated TEL/PDGFR protein was subjected to phosphoamino acid analysis. As shown in Figure 2B, in vitro autophosphorylation occurred entirely on tyrosine residues. Phosphoamino acid analysis of the F8 variant showed that this fusion protein also autophosphorylated on tyrosine residues (data not shown). This result confirmed the activity of the TEL/PDGFR fusion protein as a protein-tyrosine kinase. View larger version (39K): [in this window] [in a new window]   Figure 2. In vitro kinase activity of wild-type TEL/PDGFR fusion protein in Ba/F3 cells. (A) Cells were lysed and immunoprecipitated with antibody recognizing the PDGFR cytoplasmic domain. Immunoprecipitates were washed, subjected to in vitro phosphorylation with -[32P]-ATP, and separated by SDS-PAGE. (B) Radiolabeled wild-type TEL/PDGFR was excised from the gel, acid hydrolyzed to constituent phosphoamino acids, and separated by 2-dimensional electrophoresis. (C) Immune complex kinase assay was performed as above using lysates from 32D cells that express TEL/PDGFR variants. Phosphorylation of exogenous purified GST-p97 (GST-Gab2) was determined. Expression of TEL/PDGFR and variants was equivalent in each of the cell lines (data not shown). We next assayed for any attenuation of protein-tyrosine kinase activity that might result from the TyrPhe substitution. Although each of the TEL/PDGFR variants was able to autophosphorylate itself in an immune complex kinase assay (data not shown), the variable expression of the TEL/PDGFR fusion proteins in Ba/F3 cells complicated quantitative assessment of enzymatic activity. Therefore, we used a series of 32D myeloid cell lines that were stably transformed with wild-type, F2, F7, and F8 TEL/PDGFR fusions. These 32D cell lines expressed equivalent levels of TEL/PDGFR fusion protein (Figure 4), and extracts from these cells were therefore used in immune-complex kinase assays. The TEL/PDGFR fusion proteins were immunoprecipitated with antibody against the carboxy terminal domain of the native PDGFR, and immune complex kinase assays were performed with -[32P]-ATP and a purified GST-p97 (GST-Gab2) fusion protein as an exogenous substrate. As shown in Figure 2C, TyrPhe substitution in the TEL/PDGFR variants produced no attenuation in protein-tyrosine kinase activity directed against GST-Gab2. Similar results were obtained by performing in vitro kinase reactions with unlabeled ATP and then immunoblotting the exogenous substrate with the 4G10 antiphosphotyrosine antibody (data not shown). Therefore, these findings demonstrate that the attenuation of cell transformation by the F7 and F8 TEL/PDGFR variants was not due to loss of protein-tyrosine kinase activity. Transformation by TEL/PDGFR causes hyperphosphorylation of STAT5 on tyrosine residues The above findings indicated that the juxtamembrane tyrosine residues in TEL/PDGFR were critical for full transformation of Ba/F3 cells. Comparable tyrosine residues in the native PDGFR are critical for the activation of the STAT5 transcription factor.24 To assess the potential role of STAT5 phosphorylation on TEL/PDGFR signaling, Ba/F3 cells that express each of the TEL/PDGFR variants were immunoprecipitated with antibody against STAT5 and were immunoblotted with the antiphosphotyrosine antibody 4G10. Ba/F3 cells that expressed the native TEL/PDGFR fusion showed hyperphosphorylation of STAT5 on tyrosine (Figure 3). Similarly, the F5 variant also caused STAT5 phosphorylation, and this result indicates that the carboxy terminal phosphorylation sites in TEL/PDGFR are dispensable for STAT5 activation. In contrast, only minimal phosphorylation of STAT5 was observed in cells that expressed the F2, F7, or F8 variants, and this result indicates that the juxtamembrane Tyr579 and Tyr581 sites are critical for phosphorylation of STAT5 by the TEL/PDGFR fusion. View larger version (33K): [in this window] [in a new window]   Figure 3. Phosphorylation of STAT5 by TEL/PDGFR in Ba/F3 cells. Ba/F3 cells that express TEL/PDGFR were lysed and immunoprecipitated with antibody against STAT5. The immune complex was probed with either 4G10 antiphosphotyrosine (anti-PTYR) antibody (top) or anti-STAT5 antibody (bottom). STAT5 is hyperphosphorylated in 32D myeloid cells that are transformed with the TEL/PDGFR fusion protein Because TEL/PDGFR expression is associated with myeloid transformation in the murine BMT model21 and in human CMML, we wished to confirm the hyperphosphorylation of STAT5 in the murine 32D myeloid cell line. 32D cells that expressed the wild-type or variant TEL/PDGFR were immunoprecipitated with antibody to STAT5 and immunoblotted with the 4G10 antiphosphotyrosine antibody. Similar to the results in Ba/F3 cells shown above, TEL/PDGFR transformation of 32D cells was associated with hyperphosphorylation of STAT5. Moreover, TyrPhe substitution at the juxtamembrane sites in the F2, F7, and F8 variants abrogated STAT5 hyperphosphorylation on tyrosine residues (Figure 4). Although F5 TEL/PDGFR was expressed at a lower level compared to the other variants in 32D cells, this low level of F5 expression was sufficient to cause hyperphosphorylation of STAT5. Similar results were obtained by assessing STAT5 binding to DNA by EMSA (data not shown). Thus, the potential phosphotyrosine sites in TEL/PDGFR required for STAT5 hyperphosphorylation in 32D myeloid cells are identical to those required for STAT5 phosphorylation in Ba/F3 cells. View larger version (41K): [in this window] [in a new window]   Figure 4. STAT5 phosphorylation in 32D cells. (A) 32D myeloid cells that expressed TEL/PDGFR variants were lysed and immunoblotted with antibody against TEL/PDGFR. (B) Cell lysates were also immunoprecipitated with antibody against STAT5 and immunoblotted with antibody against phosphotyrosine or (C) STAT5. Arrow indicates hyperphosphorylated STAT5. PI3K tyrosine phosphorylation and association with TEL/PDGFR requires carboxy terminal phosphorylation of TEL/PDGFR The findings described above also indicated the critical role of the carboxy terminal tyrosine residues (within the kinase insert domain and carboxy terminal tail) in the transformation of Ba/F3 cells by TEL/PDGFR. The tyrosine residues 740 and 751 in the kinase insert are necessary for interaction with PI3K by the native PDGFR.25-27 To assess the role of PI3K in signaling by the TEL/PDGFR, the level of tyrosine phosphorylation of the 85-kd subunit of PI3K was measured. Ba/F3 cell lysates were immunoprecipitated with antibody against PI3K and were then immunoblotted with antibody against phosphotyrosine (Figure 5). Transformation by the wild-type or F2 variant of the TEL/PDGFR protein was associated with increased p85 PI3K tyrosine phosphorylation. However, transformation by the F5, F7, and F8 variant fusions did not cause increased tyrosine phosphorylation of PI3K. PI3K was expressed at equivalent levels in each of these cell lines. View larger version (37K): [in this window] [in a new window]   Figure 5. PI3K phosphorylation by TEL/PDGFR. PI3K tyrosine phosphorylation and association with TEL/PDGFR fusion proteins in Ba/F3 cells. (A) Ba/F3 cell lysates were immunoprecipitated with antibody against the 85-kd subunit of PI3K and immunoblotted with antibody against phosphotyrosine. (B) PI3K immunoprecipitates were immunoblotted with antibody against p85PI3K to assess relative expression and immunoprecipitation. (C) Ba/F3 cells were immunoprecipitated with antibody against the PDGFR cytoplasmic domain and immunoblotted with antibody against p85PI3K. The TEL/PDGFR and F2 variant also associated with the p85 subunit of PI3K (Figure 5). This interaction was dependent on the intrinsic kinase activity of the fusion protein, because the Arg634 kinase inactive mutant was unable to associate with PI3K. In contrast, the F5, F7, and F8 variants did not associate with PI3K. Collectively, these results show that the presence of the carboxy terminal tyrosine residues in the TEL/PDGFR fusion protein is necessary for tyrosine phosphorylation of and association with the p85 subunit of PI3K. Signaling through PLC tyrosine phosphorylation requires carboxy terminal phosphorylation of TEL/PDGFR Mitogenic signaling by the native PDGFR protein occurs through activation of PLC, and the engagement of PLC is mediated by tyrosine phosphorylation in the carboxy terminal tail. To determine the role of this signaling event in transformation of Ba/F3 cells by the TEL/PDGFR fusion protein, cell lysates were immunoprecipitated with antibody against PLC and immunoblotted with antibody against phosphotyrosine (Figure 6). Transformation of Ba/F3 cells by the wild-type or F2 TEL/PDGFR fusion was associated with increased tyrosine phosphorylation of PLC. This signaling event required TEL/PDGFR kinase activity because the Arg634 kinase inactive variant did not phosphorylate PLC. The transforming variants F5, F7, and F8 also caused no elevation in PLC tyrosine phosphorylation. PLC was expressed equivalently in each of the Ba/F3 cell lines (Figure 6). Thus, signaling through PLC required the presence of the carboxy terminal tyrosine residues in the TEL/PDGFR fusion protein. View larger version (33K): [in this window] [in a new window]   Figure 6. Tyrosine phosphorylation of PLC. Ba/F3 cells were lysed, immunoprecipitated with antibody against PLC, and immunoblotted with antibody against phosphotyrosine (top). PLC expression was assessed by immunoblotting whole cell lysates with antibody against PLC (bottom). SHP-2 is tyrosine phosphorylated by each of the TEL/PDGFR variants To assess the role of SHP-2 in TEL/PDGFR signaling, Ba/F3 cell lysates were immunoprecipitated with anti-SHP-2 and immunoblotted with antiphosphotyrosine antibody (Figure 7). SHP-2 showed an increased content of phosphotyrosine in Ba/F3 cells transformed by wild-type TEL/PDGFR compared with vector-control cells or cells transformed with the kinase-inactive Arg634 variant. Moreover, each of the transforming variants (F2, F5, F7, and F8) was associated with elevated SHP-2 tyrosine phosphorylation. There was equivalent expression of SHP-2 in each of these cell lines. Thus, tyrosine phosphorylation of SHP-2 did not absolutely require these 8 major autophophosphorylation sites that are present in the native PDGFR. View larger version (36K): [in this window] [in a new window]   Figure 7. Tyrosine phosphorylation of SHP-2. Ba/F3 cell lysates were immunoprecipitated with antibody against SHP-2 and immunoblotted with antibody against phosphotyrosine (top) or against SHP-2 (bottom). Each of the TEL/PDGFR variants is bound to the Grb2 adaptor molecule in vivo The small adaptor molecule Grb2 forms a stable complex with the Sos nucleotide exchange factor and can mediate signaling from protein-tyrosine kinases through Ras.13 Grb2 can bind to the native PDGFR directly at the phosphorylated Tyr71628 or indirectly through a complex with Shc29,30 or with SHP-2.31,32 Similarly, Grb2 was found in a physical complex with the TEL/PDGFR fusion protein (Figure 8). Surprisingly, each of the TEL/PDGFR variants (including the F8 variant) was associated with the Grb2 adaptor molecule in an immune complex. Thus, although the major phosphorylation sites present in the native PDGFR may mediate association of Grb2 with TEL/PDGFR, Grb2 can also interact directly or indirectly with other potential sites in the TEL/PDGFR protein. View larger version (31K): [in this window] [in a new window]   Figure 8. Association of TEL/PDGFR with the Grb2 adaptor protein. Ba/F3 cell lysates were immunoprecipitated with antibody against Grb2 and immunoblotted with antibody against the PDGFR cytoplasmic domain (top). Expression of Grb2 was determined in whole cell lysates by immunoblotting with antibody against Grb2 (bottom).     Discussion Top Abstract Introduction Materials and methods Results Discussion References The results presented here indicate that multiple phosphorylation sites in the TEL/PDGFR fusion protein are required for efficient hematopoietic transformation in cell culture, and these data correlate with transformation in a murine BMT assay of leukemogenesis.21 Progressive conservative substitution of tyrosine residues in TEL/PDGFR at major phosphorylation sites present in the native PDGFR caused incremental attenuation of IL-3-independent hematopoietic outgrowth. These same substitutions also had profound effects on latency and phenotype in the murine BMT model. However, one potential explanation for the progressive loss of hematopoietic transformation in the TEL/PDGFR variant series is that there is progressive disruption of protein tyrosine kinase activity due to the TyrPhe substitutions. For example, F2 substitutions in the native PDGFR have been reported to markedly attenuate kinase activity in response to ligand stimulation,33 although these tyrosines are not necessary for bovine papillomavirus E5-stimulated tyrosine kinase activation of PDGFR or mitogenic signaling in Ba/F3 cells.34 In addition, Tyr857 in the native PDGFR, which is preserved in each of the F-series mutants of TEL/PDGFR, is necessary for the protein-tyrosine kinase activity of the native PDGFR.35 We used a series of 32D myeloid cell extracts (with uniform levels of TEL/PDGFR expression) to assay for phosphorylation of an exogenous substrate in an immune-complex kinase assay, and the results presented here indicate that there was no loss of protein-tyrosine kinase activity in the TEL/PDGFR mutants. Thus, the substitution of major phosphotyrosine interaction sites in the TEL/PDGFR fusion attenuates activation of signaling intermediates without grossly altering kinase catalytic activity. We observed in the murine BMT assay that any TEL/PDGFR mutant that had TyrPhe substitutions at positions 579/581 was incapable of causing myeloid disease, and it instead produced long-latency lymphoproliferative disease.21 As noted above, these findings cannot be explained by a decrement in tyrosine kinase activity. These residues are known to mediate STAT5 activation by the native PDGFR,24 and we tested STAT5 activation by the TEL/PDGFR to determine whether this signaling event might correlate with phenotypic differences. The findings presented here indicate that the STAT5 transcription factor is hyperphosphorylated in cells that express the wild-type and F5 variant of TEL/PDGFR but not in the F2, F7, and F8 variants. The tyrosine residues corresponding to Tyr579 and Tyr581 in the native PDGFR are critical for full phosphorylation of STAT5. Thus, activation of STAT5 in hematopoietic cell culture correlates with transformation of myeloid lineage cells in the murine BMT model.21 These findings are consistent with recent results indicating the critical role of STAT5 in generation of murine myeloproliferative disease by the TEL/Jak2 fusion protein.10 The use of STAT5 knock-out mice in a murine BMT model will be of particular value to further assess the role of STAT5 in myeloid cell transformation by TEL/PDGFR. The cytoplasmic tyrosine kinases Src, Yes, and Fyn bind to phosphorylated tyrosine residues at Tyr579 and Tyr581 in the juxtamembrane portion of the native PDGFR,33 and it is possible that disruption of analogous sites in TEL/PDGFR attenuates signaling through a Src family member. However, we have not been able to detect TEL/PDGFR-dependent activation of Lyn or Fyn kinases that are expressed in Ba/F3 cells (data not shown). Like the PDGFR protein, TEL/PDGFR expression in Ba/F3 cells is associated with tyrosine hyperphosphorylation of and association with p85 PI3K and with tyrosine phosphorylation of PLC. The phosphorylation of these signaling intermediates is lost in the F5, F7, and F8 variants of TEL/PDGFR, and this result indicates that the carboxy terminal phosphorylation sites present in the native PDGFR are necessary for engagement of PLC and PI3K in cells that express TEL/PDGFR. The F5 variant was impaired in its ability to support outgrowth of IL-3-independent Ba/F3 cells, and there was diminished myeloid cell transformation by the F5 variant in the murine BMT model.21 In contrast, the F5 PDGFR is able to support the survival of Ba/F3 cells in the presence of v-sis or E5 bovine papillomavirus oncoproteins, despite the abrogation of PI3K and PLC signaling.34 PLC and PI3K signaling may contribute to myeloid transformation by TEL/PDGFR in the mouse BMT model. Abrogation of these pathways, alone or combined with loss of STAT5 activation in the F7 and F8 mutants, extends the latency of Ba/F3 cell outgrowth. The F8 TEL/PDGFR variant was phosphorylated on tyrosine residues in vivo (Figure 1D) and in the immune-complex kinase assay (data not shown), and deletion of the canonical Grb2 interaction site at Tyr716 of the native PDGFR caused no diminution of Grb2 binding to the TEL/PDGFR fusion protein. Thus, there are remaining potential sites in F8 for phosphotyrosine-dependent interaction with signaling intermediates such as Grb2. Moreover, a secondary set of novel autophosphorylation sites may have been revealed in F8 TEL/PDGFR; the compensatory phosphorylation of novel tyrosine residues has been reported for the F5 PDGFR.36 The TEL domain may also contain phosphorylation sites that mediate interaction with signaling proteins. This conjecture is supported by the finding that tyrosine residues 17 and 27 in TEL/PDGFR serve as autophosphorylation sites, although mutation of these residues does not impair the ability of TEL/PDGFR to cause IL-3-independent cell growth.37 Collectively, these data indicate that the activation of a minimal combination of signaling intermediates by TEL/PDGFR is required for full transforming ability in the Ba/F3 system, as well as in primary hematopoietic cells in the murine BMT assay. For example, the F2 and the F5 mutants had similar attenuation of their ability to confer factor-independent growth of Ba/F3 cells. Moreover, the F7 mutant had even more significant impairment of IL-3-independent cell outgrowth, and these findings indicate that the juxtamembrane and carboxy terminal phosphorylation sites in the TEL/PDGFR fusion protein are necessary for robust transformation. Correlation of these data with activation of SH2-containing signaling intermediates suggests that activation of either STAT5 or engagement of PI3K and PLC yields a similarly attenuated potency for transformation in the Ba/F3 assay, whereas global engagement of these signaling intermediates by the wild-type TEL/PDGFR mediates the fully transformed phenotype. Moreover, the phosphorylated tyrosine residues in the TEL/PDGFR fusion might interact with other signaling intermediates other than those that have been characterized here. The overall transformed phenotype may be modulated by additional signaling events because nuclear factor-B38 and JNK/SAPK39 have been reported to be activated by the TEL/PDGFR fusion protein. We have assessed Erk1/Erk2 activation in detail by using an in vitro kinase assay and by immunoblotting with a phosphopeptide-specific antibody that recognizes activated Erk1/Erk2 (data not shown), and we have consistently observed an absence of Erk1/Erk2 activation in Ba/F3 and 32D cells that express TEL/PDGFR. These findings correlate with recent observations regarding the expression of immediate early genes by an M-CSFR/PDGFR chimera and related TyrPhe mutants.40 Although it had been predicted that each signaling pathway would activate a discrete set of transcriptional targets, Fambrough and coworkers40 demonstrated that the TyrPhe chimeric protein mutants activated a nearly identical set of immediate early genes, but there was a quantitative decrease in the level of expression of these genes in the F5 mutant compared with wild-type chimeric protein. The hypothesis that overall signal strength contributes to the physiologic consequences of PDGFR activation is in consonance with the observations of TEL/PDGFR mutants both in the context of Ba/F3 cells and in primary murine hematopoietic cells. In summary, we have shown that multiple signaling pathways involving STAT5, SHP-2, PLC, PI3K, and Grb2 are engaged in hematopoietic cells that are transformed by TEL/PDGFR. STAT5, PLC, and PI3K appear to functionally synergize both in the transformation of Ba/F3 cells to IL-3 independence and in myeloid transformation in the murine BMT model.     Acknowledgments We thank Ben Neel, James Griffin, and Alan D'Andrea for valuable comments and critical review.     Footnotes Submitted September 18, 2000; accepted July 13, 2001. Supported in part by National Institutes of Health (NIH) grant PO1 (DK50654-01), NIH grant K08CA73749-01 (M.C.), and NIH grant K08-CA82261-02 (D.W.S.). D.W.S. is a Scholar of the American Society of Hematology. D.G.G. is an Associate Investigator in the Howard Hughes Medical Institute. The publication costs of this article were defrayed in part by page charge payment. Therefore, and solely to indicate this fact, this article is hereby marked "advertisement" in accordance with 18 U.S.C. section 1734. Reprints: D. Gary Gilliland or David W. Sternberg, Howard Hughes Medical Institute, Harvard Medical School, 4 Blackfan Cir, Rm 421, Boston, MA 02115; e-mail: gilliland{at}calvin.bwh.harvard.edu.     References Top Abstract Introduction Materials and methods Results Discussion References 1. Golub TR, Barker GF, Lovett M, Gilliland DG. Fusion of the PDGF receptor  to a novel ets-like gene, tel, in chronic myelomonocytic leukemia with t(5;12) chromosomal translocation. Cell. 1994;77:307-316[CrossRef][Medline] [Order article via Infotrieve]. 2. Carroll M, Tomasson MH, Barker GF, Golub TR, Gilliland DG. The TEL/platelet-derived growth factor  receptor (PDGFR) fusion in chronic myelomonocytic leukemia is a transforming protein that self-associates and activates PDGFR kinase-dependent signaling pathways. Proc Natl Acad Sci U S A. 1996;93:14845-14850[Abstract/Free Full Text]. 3. Jousset C, Carron C, Boureux A, et al. A domain of TEL conserved in a subset of ETS proteins defines a specific oligomerization interface essential to the mitogenic properties of the TEL-PDGFR oncoprotein. EMBO J. 1997;16:69-82[CrossRef][Medline] [Order article via Infotrieve]. 4. Lemmon MA, Schlessinger J. Regulation of signal transduction and signal diversity by receptor oligomerization. Trends Biochem Sci. 1994;19:459-463[CrossRef][Medline] [Order article via Infotrieve]. 5. Palacios R, Steinmetz M. IL3-dependent mouse clones that express B-220 surface antigen, contain Ig genes in germline configuration, and generate B lymphocytes in vivo. Cell. 1985;41:727-734[CrossRef][Medline] [Order article via Infotrieve]. 6. Buchdunger E, Zimmerman J, Mett H, et al. Selective inhibition of the platelet-derived growth factor signal transduction pathway by a protein-tyrosine kinase inhibitor of the 2-phenylaminopyrimidine class. Proc Natl Acad Sci U S A. 1995;92:2558-2562[Abstract/Free Full Text]. 7. Carroll M, Ohno-Jones S, Tamura S, et al. CGP 57148, a tyrosine kinase inhibitor, inhibits the growth of cells expressing BCR-ABL, TEL-ABL, and TEL-PDGFR fusion proteins. Blood. 1997;90:4947-4952[Abstract/Free Full Text]. 8. Ross TS, Bernard OA, Berger R, Gilliland DG. Fusion of Huntington interacting protein 1 to platelet-derived growth factor beta receptor (PDGFR) in chronic myelomonocytic leukemia with t(5;7)(q33;q11.2). Blood. 1998;91:4419-4426[Abstract/Free Full Text]. 9. Ross TS, Gilliland DG. Transforming properties of the Huntington interacting protein 1/platelet-derived growth factor beta receptor fusion protein. J Biol Chem. 1999;274:22328-22336[Abstract/Free Full Text]. 10. Schwaller J, Anastasiadou E, Cain D, et al. H4(D10S170), a gene frequently rearranged in papillary thyroid carcinoma, is fused to the platelet- derived growth factor receptor  gene in atypical chronic myeloid leukemia with t(5;10)(q33;q22). Blood. 2001;97:3910-3918[Abstract/Free Full Text]. 11. Claesson-Welsh L. Platelet-derived growth factor receptor signals. J Biol Chem. 1994;269:32023-32026[Free Full Text]. 12. Heldin C-H. Structural and functional studies on platelet-derived growth factor. EMBO J. 1992;11:4251-4259[Medline] [Order article via Infotrieve]. 13. Kazlauskas A. Receptor tyrosine kinases and their targets. Curr Opin Genet Dev. 1994;4:5-14[CrossRef][Medline] [Order article via Infotrieve]. 14. Vignais ML, Sadowski HB, Watling D, Rogers NC, Gilman M. Platelet-derived growth factor induces phosphorylation of multiple JAK family kinases and STAT proteins. Mol Cell Biol. 1996;16:1759-1769[Abstract]. 15. Darnell JE Jr. STATs and gene regulation. Science. 1997;277:1630-1635[Abstract/Free Full Text]. 16. Ilaria RL Jr, Van Etten RA. P210 and P190BCR/ABL induce the tyrosine phosphorylation and DNA binding activity of multiple specific STAT family members. J Biol Chem. 1996;271:31704-31710[Abstract/Free Full Text]. 17. Lacronique V, Boureux A, Della Valle V, et al. A TEL-JAK2 fusion protein with constitutive kinase activity in human leukemia. Science. 1997;278:1309-1312[Abstract/Free Full Text]. 18. Schwaller J, Frantsve J, Aster J, et al. Transformation of hematopoietic cells lines to growth-factor independence and induction of a fatal myelo- and lymphoproliferative disease in mice by retrovirally transduced TEL/JAK2 fusion genes. EMBO J. 1998;17:5321-5333[CrossRef][Medline] [Order article via Infotrieve]. 19. Ho JM-Y, Beattie BK, Squire JA, Frank DA, Barber DL. Fusion of the ets transcription factor TEL to Jak2 results in constitutive Jak-Stat signaling. Blood. 1999;93:4354-4364[Abstract/Free Full Text]. 20. Wilbanks AM, Mahajan S, Frank DA, Druker BJ, Gilliland DG, Carroll M. TEL/PDGFR fusion protein activates STAT1 and STAT5: a common mechanism for transformation by tyrosine kinase fusion proteins. Exp Hematol. 2000;28:584-593[CrossRef][Medline] [Order article via Infotrieve]. 21. Tomasson MH, Sternberg DW, Williams I, et al. TEL/PDGFR causes a fatal myeloproliferative disorder in mice that requires tyrosines 579/581 of PDGFR. J Clin Invest. 2000;105:423-432[Medline] [Order article via Infotrieve]. 22. Vaillancourt RR, Heasley LE, Zamarripa J, et al. Mitogen-activated protein kinase activation is insufficient for growth factor receptor-mediated PC12 cell differentiation. Mol Cell Biol. 1995;15:3644-3653[Abstract]. 23. Hunter T, Sefton BM. Transforming gene product of Rous sarcoma virus phosphorylates tyrosine. Proc Natl Acad Sci U S A. 1980;77:1311-1315[Abstract/Free Full Text]. 24. Valgeirsdottir SS, Paukku K, Silvennoinen O, Heldin C-H, Claesson-Welsh L. Activation of STAT5 by platelet-derived growth factor (PDGF) is dependent on phosphorylation sites in PDGF beta-receptor juxtamembrane and kinase insert domains. Oncogene. 1998;16:505-515[CrossRef][Medline] [Order article via Infotrieve]. 25. Fantl WJ, Escobedo JA, Martin GA, et al. Distinct phosphotyrosines on a growth factor receptor bind to specific molecules that mediate different signaling pathways. Cell. 1992;69:413-423[CrossRef][Medline] [Order article via Infotrieve]. 26. Kazlauskas A, Kashishian A, Cooper JA, Valius M. GTPase-activating protein and phosphatidylinositol 3-kinase bind to distinct regions of the platelet-derived growth factor receptor  subunit. Mol Cell Biol. 1992;12:2534-2544[Abstract/Free Full Text]. 27. Kashishian A, Kazlauskas A, Cooper JA. Phosphorylation sites in the PDGF receptor with different specificities for binding GAP and PI3 kinase in vivo. EMBO J. 1992;11:1373-1382[Medline] [Order article via Infotrieve]. 28. Arvidsson AK, Rupp E, Nanberg E, et al. Tyr-716 in the platelet-derived growth factor beta-receptor kinase insert is involved in GRB2 binding and Ras activation. Mol Cell Biol. 1994;14:6715-6726[Abstract/Free Full Text]. 29. Benjamin CW, Jones DA. Platelet-derived growth factor stimulates growth factor receptor binding protein-2 association with Shc in vascular smooth muscle cells. J Biol Chem. 1994;269:30911-30916[Abstract/Free Full Text]. 30. Yokote K, Mori S, Hansen K, et al. Direct interaction between Shc and the platelet-derived growth-factor -receptor. J Biol Chem. 1994;269:15337-15343[Abstract/Free Full Text]. 31. Li W, Nishimura R, Kashishian A, et al. A new function for a phosphotyrosine phosphatase: linking GRB2-Sos to a receptor tyrosine kinase. Mol Cell Biol. 1994;14:509-517[Abstract/Free Full Text]. 32. Bennett AM, Tang TL, Sugimoto S, Walsh CT, Neel BG. Protein-tyrosine-phosphatase SHPTP2 couples platelet-derived growth factor receptor beta to Ras. Proc Natl Acad Sci U S A. 1994;91:7335-7339[Abstract/Free Full Text]. 33. Mori S, Rönnstrand L, Yokote K, et al. Identification of two juxtamembrane autophosphorylation sites in the PDGF -receptor: involvement in the interaction with Src family tyrosine kinases. EMBO J. 1993;12:2257-2264[Medline] [Order article via Infotrieve]. 34. Drummond-Barbosa D, Vaillancourt RR, Kazlauskas A, DiMaio D. Ligand-independent activation of the platelet-derived growth factor  receptor: requirements for bovine papillomavirus E5induced mitogenic signaling. Mol Cell Biol. 1995;15:2570-2581[Abstract]. 35. Kazlauskas A, Cooper JA. Autophosphorylation of the PDGF receptor in the kinase insert region regulates interaction with cell proteins. Cell. 1989;58:1121-1133[CrossRef][Medline] [Order article via Infotrieve]. 36. Valius M, Kazlauskas A. Phospholipase C-1 and phosphatidylinositol 3 kinase are the downstream mediators of the PDGF receptor's mitogenic signal. Cell. 1993;73:321-334[CrossRef][Medline] [Order article via Infotrieve]. 37. Sjöblom T, Boureux A, Rönnstrand L, Heldin C-H, Ghysdael J, Östman A. Characterization of the chronic myelomonocytic leukemia associated TEL/PDGFR fusion protein. Oncogene. 1999;18:7055-7062[CrossRef][Medline] [Order article via Infotrieve]. 38. Besançon F, Atfi A, Gespach C, Cayre YE, Bourgeade M-F. Evidence for a role of NF-B in the survival of hematopoietic cells mediated by interleukin 3 and the oncogenic TEL/platelet-derived growth factor receptor  fusion protein. Proc Natl Acad Sci U S A. 1998;95:8081-8086[Abstract/Free Full Text]. 39. Atfi A, Prunier C, Mazars A, et al. The oncogenic TEL/PDGFR fusion protein induces cell death through JNK/SAPK pathway. Oncogene. 1999;18:3878-3885[CrossRef][Medline] [Order article via Infotrieve]. 40. Fambrough D, McClure K, Kazlauskas A, Lander ES. Diverse signaling pathways activated by growth factor receptors induce broadly overlapping, rather than independent, sets of genes. Cell. 1999;97:727-741[CrossRef][Medline] [Order article via Infotrieve]. © 2001 by The American Society of Hematology.   CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this? This article has been cited by other articles: N. Harir, C. Boudot, K. Friedbichler, K. Sonneck, R. Kondo, S. Martin-Lanneree, L. Kenner, M. Kerenyi, S. Yahiaoui, V. Gouilleux-Gruart, et al. Oncogenic Kit controls neoplastic mast cell growth through a Stat5/PI3-kinase signaling cascade Blood, September 15, 2008; 112(6): 2463 - 2473. [Abstract] [Full Text] [PDF] E. V. Barry, J. J. Clark, J. Cools, J. Roesel, and D. G. Gilliland Uniform sensitivity of FLT3 activation loop mutants to the tyrosine kinase inhibitor midostaurin Blood, December 15, 2007; 110(13): 4476 - 4479. [Abstract] [Full Text] [PDF] J. A. Cain, Z. Xiang, J. O'Neal, F. Kreisel, A. Colson, H. Luo, L. Hennighausen, and M. H. Tomasson Myeloproliferative disease induced by TEL-PDGFRB displays dynamic range sensitivity to Stat5 gene dosage Blood, May 1, 2007; 109(9): 3906 - 3914. [Abstract] [Full Text] [PDF] J. L. Rocnik, R. Okabe, J.-C. Yu, B. H. Lee, N. Giese, D. P. Schenkein, and D. G. Gilliland Roles of tyrosine 589 and 591 in STAT5 activation and transformation mediated by FLT3-ITD Blood, August 15, 2006; 108(4): 1339 - 1345. [Abstract] [Full Text] [PDF] J. D. Growney, J. J. Clark, J. Adelsperger, R. Stone, D. Fabbro, J. D. Griffin, and D. G. Gilliland Activation mutations of human c-KIT resistant to imatinib mesylate are sensitive to the tyrosine kinase inhibitor PKC412 Blood, July 15, 2005; 106(2): 721 - 724. [Abstract] [Full Text] [PDF] R. M. Stone, D. J. DeAngelo, V. Klimek, I. Galinsky, E. Estey, S. D. Nimer, W. Grandin, D. Lebwohl, Y. Wang, P. Cohen, et al. Patients with acute myeloid leukemia and an activating mutation in FLT3 respond to a small-molecule FLT3 tyrosine kinase inhibitor, PKC412 Blood, January 1, 2005; 105(1): 54 - 60. [Abstract] [Full Text] [PDF] J. J. Clark, J. Cools, D. P. Curley, J.-C. Yu, N. A. Lokker, N. A. Giese, and D. G. Gilliland Variable sensitivity of FLT3 activation loop mutations to the small molecule tyrosine kinase inhibitor MLN518 Blood, November 1, 2004; 104(9): 2867 - 2872. [Abstract] [Full Text] [PDF] J. Chen, I. R. Williams, J. L. Kutok, N. Duclos, E. Anastasiadou, S. C. Masters, H. Fu, and D. G. Gilliland Positive and negative regulatory roles of the WW-like domain in TEL-PDGF{beta}R transformation Blood, July 15, 2004; 104(2): 535 - 542. [Abstract] [Full Text] [PDF] C. Heath and N. C. P. Cross Critical Role of STAT5 Activation in Transformation Mediated by ZNF198-FGFR1 J. Biol. Chem., February 20, 2004; 279(8): 6666 - 6673. [Abstract] [Full Text] [PDF] D. W. Sternberg and D. G. Gilliland The Role of Signal Transducer and Activator of Transcription Factors in Leukemogenesis J. Clin. Oncol., January 15, 2004; 22(2): 361 - 371. [Abstract] [Full Text] [PDF] H. Wheadon and M. J. Welham The coupling of TEL/PDGF{beta}R to distinct functional responses is modulated by the presence of cytokine: involvement of mitogen-activated protein kinases Blood, August 15, 2003; 102(4): 1480 - 1489. [Abstract] [Full Text] [PDF] M. Benekli, M. R. Baer, H. Baumann, and M. Wetzler Signal transducer and activator of transcription proteins in leukemias Blood, April 15, 2003; 101(8): 2940 - 2954. [Abstract] [Full Text] [PDF] M. Mizuki, J. Schwable, C. Steur, C. Choudhary, S. Agrawal, B. Sargin, B. Steffen, I. Matsumura, Y. Kanakura, F. D. Bohmer, et al. Suppression of myeloid transcription factors and induction of STAT response genes by AML-specific Flt3 mutations Blood, April 15, 2003; 101(8): 3164 - 3173. [Abstract] [Full Text] [PDF] J. L. Kutok and J. C. Aster Molecular Biology of Anaplastic Lymphoma Kinase-Positive Anaplastic Large-Cell Lymphoma J. Clin. Oncol., September 1, 2002; 20(17): 3691 - 3702. [Abstract] [Full Text] [PDF] J. M.-Y. Ho, M. H.-H. Nguyen, J. K. Dierov, K. M. Badger, B. K. Beattie, P. Tartaro, R. Haq, B. W. Zanke, M. P. Carroll, and D. L. Barber TEL-JAK2 constitutively activates the extracellular signal-regulated kinase (ERK), stress-activated protein/Jun kinase (SAPK/JNK), and p38 signaling pathways Blood, July 30, 2002; 100(4): 1438 - 1448. [Abstract] [Full Text] [PDF] A. B. Dash, I. R. Williams, J. L. Kutok, M. H. Tomasson, E. Anastasiadou, K. Lindahl, S. Li, R. A. Van Etten, J. Borrow, D. Housman, et al. A murine model of CML blast crisis induced by cooperation between BCR/ABL and NUP98/HOXA9 PNAS, May 28, 2002; 99(11): 7622 - 7627. [Abstract] [Full Text] [PDF] This Article Abstract Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Rights and Permissions Citing Articles Citing Articles via HighWire Citing Articles via CrossRef Citing Articles via Google Scholar Google Scholar Articles by Sternberg, D. W. Articles by Gilliland, D. G. Search for Related Content PubMed PubMed Citation Articles by Sternberg, D. W. Articles by Gilliland, D. G. Related Collections Neoplasia Signal Transduction Social Bookmarking                   What's this?

	Copyright © 2001 by American Society of Hematology         Online ISSN: 1528-0020